Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR070803 plus bevacizumab-based chemotherapy versus FOLFOX plus bevacizumab as first-line treatment for advanced colorectal cancer
CTR20232088Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2023
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of nanoliposomal irinotecan in colorectal adenocarcinoma, sponsored by Hengrui Therapeutics. Started Aug 2023; status: active.
02
Drugs
nanoliposomal irinotecan
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20232088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232088.